Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study

References

• Whitehead M I, Fraser D. The effects of estrogens and progestogens on the endometrium. Modern approach to treatment. Obstet Gynecol Clin North Am 1987; 14: 299–320
   PubMed Web of Science ®Google Scholar
• Udoff L, Langenberg P, Adashi E Y. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86: 306–316
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275: 370–375
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Adami H O, Baron J A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–1137
   PubMed Web of Science ®Google Scholar
• Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomized comparison of low and standard doses. J Br Menopause Soc 2004; 10: 95–102
   PubMedGoogle Scholar
• Wells M, Sturdee D W, Barlow D H, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. BMJ 2002; 325: 239
   PubMed Web of Science ®Google Scholar
• Anderson G L, Judd H L, Kaunitz A M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1739–1748
   PubMed Web of Science ®Google Scholar
• Hill D A, Weiss N S, Beresford S A, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000; 183: 1456–1461
   PubMed Web of Science ®Google Scholar
• Powers M S, Schenkel L, Darley P E, Good W R, Balestra J C, Place V A. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152: 1099–1106
   PubMed Web of Science ®Google Scholar
• Cedars M I, Judd H L. Non-oral routes of estrogen administration. Obstet Gynecol Clin North Am 1987; 14: 269–298
   PubMed Web of Science ®Google Scholar
• Cust M P, Gangar K F, Whitehead M I. Administration of steroids by skin patches. Res Reprod 1989; 21: 1–2
   Google Scholar
• Stumpf P G. Pharmacokinetics of estrogen. Obstet Gynecol 1990; 75: 9–14S
   PubMed Web of Science ®Google Scholar
• Shakir Y A, Samsioe G, Nerbrand C, Lidfeldt J. Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: Women's Health in the Lund Area study. Menopause 2004; 11: 549–555
   PubMed Web of Science ®Google Scholar
• Van Erpecum K J, Van Berge Henegouwen G P, Verschoor L, Stoelwinder B, Willekens F L. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100: 482–488
   PubMed Web of Science ®Google Scholar
• Kurman R J. Blaustein's Pathology of the Female Genital Tract4th edn. Springer Verlag, New York, 1994:1–1280
   Google Scholar
• Dallenbach-Hellweg G, Poulsen H. Atlas of Endometrial Histopathology2nd edn. Springer, Berlin 1996
   Google Scholar
• Kurman R J, Solomon D. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses. Springer Verlag, New York 1994
   Google Scholar
• Committee for Proprietary Medical Products (CPMP) Guideline. Points to consider on Hormone Replacement Therapy. 1997, November 19
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. 2006, May 1
   Google Scholar
• Munstedt K, Grant P, Woenckhaus J, Roth G, Tinneberg H R. Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol 2004; 2: 24
   PubMedGoogle Scholar
• North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003; 10: 113–132
   PubMed Web of Science ®Google Scholar
• Lethaby A, Suckling J, Barlow D, Farquhar C M, Jepson R G, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; 3, CD000402
   PubMedGoogle Scholar
• Korhonen M O, Symons J P, Hyde B M, Rowan J P, Wilborn W H. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 1997; 176: 377–380
   PubMed Web of Science ®Google Scholar
• Archer D F, Furst K, Tipping D, Dain M P, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999; 94: 498–503
   PubMed Web of Science ®Google Scholar
• Shulman L P, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002; 9: 195–207
   PubMed Web of Science ®Google Scholar
• Mattsson LÅ, Bohnet H G, Gredmark T, Torhorst J, Hornig F, Huls G. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. Obstet Gynecol 1999; 94: 61–65
   PubMed Web of Science ®Google Scholar
• Archer D F, Pickar J H, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994; 83: 686–692
   PubMed Web of Science ®Google Scholar
• Shau W Y, Hsieh C C, Hsieh T T, Hung T H, Huang K E. Factors associated with endometrial bleeding in continuous hormone replacement therapy. Menopause 2002; 9: 188–194
   PubMed Web of Science ®Google Scholar
• Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002; 3: 303–311
   PubMed Web of Science ®Google Scholar
• Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
   PubMed Web of Science ®Google Scholar
• Chlebowski R T, Hendrix S L, Langer R D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289: 3243–3253
   PubMed Web of Science ®Google Scholar
• Colditz G A. Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res 2005; 11: 909–917s
   Web of Science ®Google Scholar
• American Cancer Society. Cancer facts and figures 2004. American Cancer Society Inc, AtlantaGA, USA 2004; 14, (www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf)
   Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–1059
   PubMed Web of Science ®Google Scholar
• Crandall C. Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. J Womens Health (Larchmt) 2003; 12: 723–747
   PubMed Web of Science ®Google Scholar
• Harvey J, Scheurer C, Kawakami F T, Quebe-Fehling E, Ibarra de Palacios P, Ragavan V V. Hormone replacement therapy and breast density changes. Climacteric 2005; 8: 185–192
   PubMed Web of Science ®Google Scholar
• Erberich L C, Alcantara V M, Picheth G, Scartezini M. Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels. Clin Chem Lab Med 2002; 40: 446–451
   PubMed Web of Science ®Google Scholar
• Munk-Jensen N, Ulrich L G, Obel E B, Nielsen S P, Edwards D, Meinertz H. Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women: effect of plasma lipoproteins in a two-year placebo-controlled trial. Am J Obstet Gynecol 1994; 171: 132–138
   PubMed Web of Science ®Google Scholar
• Brynhildsen J, Hammar M. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use. Maturitas 2005; 50: 344–352
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Casals E, Sanllehy C, Duran M, Fortuny A, Vanrell J A. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate. J Reprod Med 1996; 41: 833–838
   PubMed Web of Science ®Google Scholar
• Bhathena R, Anklesaria B S, Ganatra A M, Pinto R. The influence of medroxyprogesterone acetate on the effects of transdermal oestradiol replacement therapy on plasma lipids. J Obstet Gynaecol 1998; 18: 141–145
   PubMedGoogle Scholar